Form 8-K - Current report:
SEC Accession No. 0001193125-25-261723
Filing Date
2025-11-03
Accepted
2025-11-03 08:02:32
Documents
12
Period of Report
2025-11-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vor-20251102.htm   iXBRL 8-K 47900
2 EX-99.1 vor-ex99_1.htm EX-99.1 16482
3 GRAPHIC img246614764_0.jpg GRAPHIC 97554
  Complete submission text file 0001193125-25-261723.txt   310081

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vor-20251102.xsd EX-101.SCH 24847
14 EXTRACTED XBRL INSTANCE DOCUMENT vor-20251102_htm.xml XML 4705
Mailing Address 500 BOYLSTON STREET SUITE 1350 BOSTON MA 02116
Business Address 500 BOYLSTON STREET SUITE 1350 BOSTON MA 02116 617-655-6580
Vor Biopharma Inc. (Filer) CIK: 0001817229 (see all company filings)

EIN.: 811591163 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39979 | Film No.: 251442175
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)